Scarica l'app Stockscreener
3.62
2.95%
-0.11
Taysha Gene Therapies Inc Borsa (TSHA) Ultime notizie
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Four new hires get Taysha stock awards tied to 384,000 shares, plus rights to buy more. - Stock Titan
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Taysha Gene Therapies: A Bull Case That Does Not Require The Fastest Approval - Seeking Alpha
These 3 Risky Stocks Could Be Sitting on 100% Upside - inkl
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Taysha Gene Therapies Insiders Sell US$1.9m Of Stock, Possibly Signalling Caution - Moomoo
Certain Common Stock of Taysha Gene Therapies, Inc. are subject to a Lock-Up Agreement Ending on 24-AUG-2026. - www.marketscreener.com
Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap DownShould You Sell? - MarketBeat
TSHA-102 Rett Data, Expanded Catalent Deal And New Financing Might Change The Case For Investing In Taysha Gene Therapies (TSHA) - simplywall.st
Taysha (TSHA) Results Review: Reported EPS Misses Expectations; Trading Move: The Market Price Advances 3.96% in Latest TradingAnalyst Drop Coverage - vinanet.vn
Taysha Gene Therapies (TSHA) Q2 2026 Earnings Call - AOL.com
Taysha Gene Therapies (TSHA) Q2 2026 Earnings Call - The Globe and Mail
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
RA Capital reports 9.99% TSHA stake in Taysha Gene Therapies (TSHA) - Stock Titan
BofA Securities Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating - Moomoo
Taysha Gene Therapies (TSHA) Drops 6.5% as Gene Therapy Stock Approaches Key Support at $5.69Bull Flag - Vinanet
Morgan Stanley (TSHA holder) discloses 5.1% Taysha Gene Therapies stake in 13G/A - stocktitan.net
Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 6.6%Here's Why - MarketBeat
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Taysha Gene Therapies (TSHA) After Rett Trial Progress And Catalent Expansion Is The Undervalued Case Stronger - Yahoo Finance
Goldman Sachs Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $13 - Moomoo
Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Down Following Weak Earnings - MarketBeat
Why is Taysha Gene Therapies stock sliding today? By Investing.com - Investing.com Australia
Why is Taysha Gene Therapies stock sliding today? - Investing.com
Why is Taysha Gene Therapies stock sliding today? By Investing.com - Investing.com India
Why is Taysha Gene Therapies stock sliding today? By Investing.com - Investing.com Canada
Taysha Gene Therapies, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Taysha Gene Therapies, Inc. Stock 12‑Month Price Target Raised to $13.33, Implies 100% Upside - TradingView
Renaissance Technologies LLC Purchases 242,103 Shares of Taysha Gene Therapies, Inc. $TSHA - MarketBeat
TSHA SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Taysha Gene Therapies Inc (TSHA) (Q2 2026) Earnings Call Highlights: Rett Syndrome Program ... By GuruFocus - Investing.com Canada
Taysha Gene Therapies Inc (TSHA) (Q2 2026) Earnings Call Highlights: Rett Syndrome Program ... - Yahoo Finance
Taysha Gene Therapies Inc (TSHA) (Q2 2026) Earnings Call Highlig - GuruFocus
Taysha Gene Therapies Q2 2026 Earnings Call Transcript - MarketBeat
TSHA Looks 873.5% Overvalued on GF Value™ - GuruFocus
Taysha Gene Therapies Q2 Earnings Call Highlights - MarketBeat
Taysha Gene Therapies Q2 Earnings Call Highlights - TradingView
Taysha Gene Therapies Q2 Earnings Call Highlights - Yahoo Finance
TSHA: Completed pivotal trial dosing, secured $230M financing, and advanced toward BLA submission - TradingView
Earnings call transcript: Taysha Gene Therapies misses Q2 2026 EPS forecast - Investing.com
Taysha Gene Therapies Q2 Results: Net Loss Widens To $46.6 Million - scanx.trade
Earnings Flash (TSHA) Taysha Gene Therapies Posts Q2 Loss of $0.13, vs. FactSet Est of $0.11 Loss - marketscreener.com
Taysha Gene Therapies (TSHA) Q2 2026 Earnings Call - The Globe and Mail
Taysha Gene Therapies (NASDAQ:TSHA) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS - MarketBeat
Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Taysha Gene Therapies Q2 net loss widens on higher R&D costs - TradingView
Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Yahoo Finance
Taysha Gene faces earnings test as Rett therapy advances By Investing.com - Investing.com Canada
0.14%
13.78%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):